Watch DFPH. Know when insiders buy.
One email the day a filing lands. Free.
DFPH
Starling Oncology, Inc.
2.01
+0.00 +0.00%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $204.8MP/E —DIV YIELD —FCF YIELD -1.60%REV TTM $587.2M +38.4%NET INCOME −$36.3MNET DEBT $79.8M52W 1.34 – 2.01SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $161.3M | +34.6% | — | −$4.6M | −$9.8M | — | -0.08 | $11.9M | $908K | $11M | Aug 6 |
| Q1 2026 · Mar 31 | $147.4M | +41.2% | — | −$6.5M | −$2.5M | — | -0.02 | −$2.2M | $1M | −$3.3M | Aug 6 |
| Q4 2025 · Dec 31derived | $142M | +41.6% | — | −$6.9M | −$7.5M | — | -0.05 | $3.2M | $1.1M | $2.2M | Mar 12 |
| Q3 2025 · Sep 30 | $136.6M | +36.7% | — | −$8.1M | −$16.5M | — | -0.14 | −$12.6M | $604K | −$13.2M | Nov 13 |
| Q2 2025 · Jun 30 | $119.8M | +21.5% | — | −$11.2M | −$17M | — | -0.15 | −$10.2M | $1.2M | −$11.4M | Aug 6 |
| Q1 2025 · Mar 31 | $104.4M | +10.3% | — | −$9.9M | −$19.6M | — | -0.21 | −$5M | $328K | −$5.3M | Aug 6 |
| Q4 2024 · Dec 31 | $100.3M | +16.9% | — | −$11.9M | −$13.2M | — | -0.15 | $4M | $1.8M | $2.2M | Mar 12 |
| Q3 2024 · Sep 30 | $99.9M | +21.8% | — | −$13.9M | −$16.1M | — | -0.18 | $819K | −$402K | $1.2M | Nov 13 |
| Q2 2024 · Jun 30 | $98.6M | — | — | −$16.4M | −$15.5M | — | -0.17 | −$15.7M | $1.8M | −$17.5M | Nov 13 |
| Q1 2024 · Mar 31 | $94.7M | — | — | −$18M | −$19.9M | — | -0.22 | −$15.9M | $610K | −$16.5M | Nov 13 |
| Q4 2023 · Dec 31derived | $85.8M | — | — | −$15.3M | −$18.8M | — | -0.21 | −$3.9M | $861K | −$4.8M | Mar 26 |
| Q3 2023 · Sep 30 | $82M | — | — | −$13.9M | −$17.4M | — | -0.19 | −$8.3M | $930K | −$9.2M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $502.7M | — | −$36.1M | −$60.6M | -12.1% | -0.54 | −$24.6M | $3.2M | −$27.8M | — | — |
| FY2024 · to Dec 31 | $393.4M | — | −$60.1M | −$64.7M | -16.4% | -0.71 | −$26.5M | $3.8M | −$30.3M | $0 | — |
| FY2023 · to Dec 31 | $324.2M | — | −$77M | −$83.1M | -25.6% | -0.92 | −$36.3M | $4.6M | −$40.9M | $1M | — |
| FY2022 · to Dec 31 | $252.5M | — | −$82M | $152K | 0.1% | -0.21 | −$61.8M | $5.5M | −$67.3M | $9M | — |
| FY2021 · to Dec 31 | $203M | — | −$45.9M | −$10.9M | -5.4% | -0.16 | −$32.7M | $2.8M | −$35.5M | $0 | — |
| FY2020 · to Dec 31 | $187.5M | — | −$8.2M | −$14.3M | -7.6% | -0.24 | $508K | $1.2M | −$686K | — | — |
Every number comes from Starling Oncology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.